US 11,883,488 B2
Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV core antigen
Edward A. Clark, Seattle, WA (US); Deborah L. Fuller, Seattle, WA (US); Che-Leung Law, Seattle, WA (US); and Amanda Mak, Seattle, WA (US)
Assigned to Abacus Bioscience, Inc., Seattle, WA (US)
Filed by UNIVERSITY OF WASHINGTON, Seattle, WA (US); and ABACUS BIOSCIENCE, INC., Sammamish, WA (US)
Filed on Apr. 15, 2022, as Appl. No. 17/721,554.
Application 17/721,554 is a division of application No. 16/088,386, granted, now 11,324,819, previously published as PCT/US2016/063246, filed on Nov. 22, 2016.
Claims priority of provisional application 62/319,160, filed on Apr. 6, 2016.
Prior Publication US 2022/0241403 A1, Aug. 4, 2022
Int. Cl. A61K 39/12 (2006.01); A61K 39/29 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); C07K 16/28 (2006.01); C12N 7/00 (2006.01)
CPC A61K 39/292 (2013.01) [A61K 39/001129 (2018.08); A61K 39/39 (2013.01); C07K 16/2896 (2013.01); C12N 7/00 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C12N 2730/10134 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A nucleic acid encoding a polypeptide comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:3, residues 1-418.